Access the full text.
Sign up today, get DeepDyve free for 14 days.
C. Gracia, E. Freeman (2004)
Acute consequences of the menopausal transition: the rise of common menopausal symptoms.Endocrinology and metabolism clinics of North America, 33 4
P. Tuntiviriyapun, K. Panyakhamlerd, S. Triratanachat, T. Chatsuwan, S. Chaikittisilpa, U. Jaisamrarn, N. Taechakraichana (2015)
Newly developed vaginal atrophy symptoms II and vaginal pH: a better correlation in vaginal atrophy?Climacteric, 18
F. Labrie, L. Derogatis, D. Archer, W. Koltun, A. Vachon, Douglas Young, L. Frenette, D. Portman, M. Montesino, I. Côté, J. Parent, L. Lavoie, A. Beauregard, C. Martel, M. Vaillancourt, J. Balser, É. Moyneur (2015)
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy.The journal of sexual medicine, 12 12
C. Christiansen, M. Christensen, N. Larsen, I. Transbøl (1982)
Pathophysiological mechanisms of estrogen effect on bone metabolism. Dose-response relationships in early postmenopausal women.The Journal of clinical endocrinology and metabolism, 55 6
D. Cella, L. Fallowfield (2007)
Recognition and management of treatment-related side effects for breast cancer patients receiving adjuvant endocrine therapyBreast Cancer Research and Treatment, 107
P. Ganz, R. Cecchini, T. Julian, R. Margolese, J. Costantino, L. Vallow, K. Albain, P. Whitworth, M. Cianfrocca, A. Brufsky, H. Gross, G. Soori, J. Hopkins, L. Fehrenbacher, Keren Sturtz, T. Wozniak, T. Seay, E. Mamounas, N. Wolmark (2016)
Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trialThe Lancet, 387
(2002)
Review article: Effects of estrogen deprivation: vasomotor symptoms, urogenital atrophy, and psychobiologic effects. Clinics in Fam Pract 4(1):27–39
F. Labrie, D. Archer, C. Bouchard, M. Fortier, L. Cusan, José-luis Gomez, G. Girard, Mira Baron, N. Ayotte, M. Moreau, Robert Dubé, I. Côté, C. Labrie, L. Lavoie, L. Berger, L. Gilbert, C. Martel, J. Balser (2009)
Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal womenMenopause, 16
H. Burger (2006)
Faculty Opinions recommendation of Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors.
D. Archer (2010)
Efficacy and tolerability of local estrogen therapy for urogenital atrophyMenopause, 17
F. Labrie, D. Archer, C. Bouchard, M. Fortier, L. Cusan, José-luis Gomez, G. Girard, Mira Baron, N. Ayotte, M. Moreau, Robert Dubé, I. Côté, C. Labrie, L. Lavoie, R. Bérubé, P. Bélanger, L. Berger, L. Gilbert, C. Martel, J. Balser (2009)
Serum steroid levels during 12-week intravaginal dehydroepiandrosterone administrationMenopause, 16
S. Birrell, L. Butler, Jonathan Harris, Grant Buchanan, W. Tilley (2007)
Disruption of androgen receptor signaling by synthetic progestins may increase risk of developing breast cancerThe FASEB Journal, 21
R. Santen, J. Pinkerton, M. Conaway, M. Ropka, L. Wisniewski, L. Demers, K. Klein (2002)
Treatment of urogenital atrophy with low-dose estradiol: preliminary resultsMenopause, 9
M. Weber, J. Limpens, J. Roovers (2014)
Assessment of vaginal atrophy: a reviewInternational Urogynecology Journal, 26
F. Labrie, C. Martel, R. Bérubé, I. Côté, C. Labrie, L. Cusan, José-luis Gomez (2013)
Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgensThe Journal of Steroid Biochemistry and Molecular Biology, 138
T. Naessén, K. Rodriguez-Macias, H. Lithell (2001)
Serum lipid profile improved by ultra-low doses of 17β-estradiol in elderly womenObstetrical & Gynecological Survey, 57
T. Naessén, Lars Berglund, U. Ulmsten (1997)
Bone loss in elderly women prevented by ultralow doses of parenteral 17beta-estradiol.American journal of obstetrics and gynecology, 177 1
N. Samaras, D. Samaras, E. Frangos, A. Forster, J. Philippe (2013)
A review of age-related dehydroepiandrosterone decline and its association with well-known geriatric syndromes: is treatment beneficial?Rejuvenation research, 16 4
G. Bachmann, S. Johnston, B. Kessel, M. Knobf, E. Stewart (2007)
The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause SocietyMenopause, 14
A. Kendall, M. Dowsett, E. Folkerd, I. Smith (2006)
Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors.Annals of oncology : official journal of the European Society for Medical Oncology, 17 4
S. Wills, A. Ravipati, P. Venuturumilli, C. Kresge, E. Folkerd, M. Dowsett, D. Hayes, D. Decker (2012)
Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator.Journal of oncology practice, 8 3
Shouzhe Lin (2008)
The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women:2007 position statement of The North American Menopause SocietyChinese Journal of Practical Gynecology and Obstetrics
D. Barton, J. Sloan, L. Shuster, P. Gill, J. Bearden, David Johnson, P. Stella, S. Terstriep, Fauzia Rana, Daniel Anderson, C. Loprinzi (2014)
Impact of vaginal dehydroepiandosterone (DHEA) on vaginal symptoms in female cancer survivors: Trial N10C1 (Alliance).Journal of Clinical Oncology, 32
O. Tan, K. Bradshaw, B. Carr (2012)
Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date reviewMenopause: The Journal of The North American Menopause Society, 19
P. Peris, L. Álvarez, A. Monegal, N. Guañabens, M. Durán, F. Pons, M. Osaba, M. Echevarría, A. Ballesta, J. Muñoz‐Gómez (1999)
Biochemical markers of bone turnover after surgical menopause and hormone replacement therapy.Bone, 25 3
D. Hu, L. Selth, G. Tarulli, R. Meech, Dhilushi Wijayakumara, Apichaya Chanawong, R. Russell, C. Caldas, Jessica Robinson, J. Carroll, W. Tilley, P. Mackenzie, Theresa Hickey (2016)
Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.Cancer research, 76 19
F. Labrie, V. Luu‐The, C. Labrie, A. Bélanger, J. Simard, Sheng-Xiang Lin, G. Pelletier (2003)
Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone.Endocrine reviews, 24 2
F. Labrie, D. Archer, C. Bouchard, M. Fortier, L. Cusan, José-luis Gomez, G. Girard, Mira Baron, N. Ayotte, M. Moreau, Robert Dubé, I. Côté, C. Labrie, L. Lavoie, L. Berger, L. Gilbert, C. Martel, J. Balser (2009)
Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophyMenopause, 16
J. Bacon (2017)
The Menopausal Transition.Obstetrics and gynecology clinics of North America, 44 2
K. Reeder-Hayes, H. Muss (2017)
Vaginal Estrogens and Aromatase Inhibitors: How Safe Is Safe Enough?JAMA oncology, 3 3
T. Hlaing, J. Compston (2014)
Biochemical markers of bone turnover – uses and limitationsAnnals of Clinical Biochemistry, 51
(2002)
Review article : Effects of estrogen deprivation : vasomotor symptoms , urogenital atrophy , and psychobiologic effects
L. Lara, B. Useche, R. Ferriani, R. Reis, M. Sá, M. Freitas, J. Silva, A. Silva (2009)
The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response.The journal of sexual medicine, 6 1
D. Barton, P. Ganz (2015)
Symptoms: Menopause, Infertility, and Sexual Health.Advances in experimental medicine and biology, 862
A. Traish, K. Fetten, M. Miner, Michael Hansen, A. Guay (2010)
Testosterone and risk of breast cancer: appraisal of existing evidence, 2
T. Naessen, K. Rodriguez-Macias, H. Lithell (2001)
Serum lipid profile improved by ultra-low doses of 17 beta-estradiol in elderly women.The Journal of clinical endocrinology and metabolism, 86 6
Background Dehydroepiandrosterone (DHEA) is helpful for evaluable blood and 46 contributed evaluable cytology and treating vaginal symptoms. This secondary analysis evaluated pH values. Circulating DHEA-S and testosterone levels were the impact of vaginal DHEA on hormone concentrations, significantly increased in those on vaginal DHEA in a dose- bone turnover, and vaginal cytology in women with a cancer dependent manner compared to PM. Estradiol was significant- history. ly increased in those on 6.5 mg/day DHEA but not in those on Methods Postmenopausal women, diagnosed with breast or 3.25 mg/day DHEA (p <0.05 and p = 0.05, respectively), and gynecologic cancer, were eligible if they reported at least not in those on AIs. Biomarkers of bone formation were un- moderate vaginal symptoms. Participants could be on tamox- changed in all arms. Maturation of vaginal cells was 100% ifen or aromatase inhibitors (AIs). Women were randomized (3.25 mg/day), 86% (6.5 mg/day), and 64% (PM); pH de- to 3.25 versus 6.5 mg/day of DHEA versus a plain moisturizer creased more in DHEA arms. (PM) control. Sex steroid hormone levels, biomarkers of bone Conclusion DHEA resulted in increased hormone concentra- formation, vaginal pH, and maturation index were collected at tions, though still in the
Supportive Care in Cancer – Springer Journals
Published: Nov 21, 2017
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.